Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sanofi : Helped by a technical support level

share with twitter share with LinkedIn share with facebook
share via e-mail
05/16/2019 | 02:45am EDT
long trade
Target price hit
Entry price : 73.8€ | Target : 76.35€ | Stop-loss : 71.6€ | Potential : 3.46%
Pursuant to the correction that has taken place in recent weeks with respect to the shares in Sanofi, further downside risk now appears limited by close and important technical support levels at 72.57 EUR.
Investors have an opportunity to buy the stock and target the € 76.35.
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Strengths
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the EUR 72.57 support.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Sanofi : Helped by a technical support level

Jordan Dufee
© Zonebourse.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (EUR)
Sales 2019 36 375 M
EBIT 2019 9 484 M
Net income 2019 4 278 M
Debt 2019 14 724 M
Yield 2019 3,87%
P/E ratio 2019 25,2x
P/E ratio 2020 17,2x
EV / Sales2019 3,21x
EV / Sales2020 3,02x
Capitalization 102 B
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 87,21  €
Last Close Price 81,42  €
Spread / Highest target 22,8%
Spread / Average Target 7,12%
Spread / Lowest Target -41,0%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI7.61%111 125
JOHNSON & JOHNSON0.48%344 174
ROCHE HOLDING LTD.14.65%241 967
MERCK AND COMPANY8.65%212 562
PFIZER-16.66%201 220
NOVARTIS15.63%197 665